Heart Failure with Preserved Ejection Fraction HFpEF - a prospective cohort

HFpEF cohort

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25965

Enrollment

1000

Registered

2019-10-17

Start date

2019-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure with Preserved Ejection Fraction

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: There are no specific inclusion criteria for the patients referred to the HFpEF outpatient clinic. All patients above 18 years that have the ability to give the informed consent will be included in the cohort and blood and urine samples for the biobank will be obtained.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Inability to give informed consent or refusal to participate in the study - Age <18 years

Design outcomes

Primary

Measure	Time frame
1.Stratify the heterogeneous group of HFpEF patients to identify specific subtypes.	—

Secondary

Measure	Time frame
2. Set up a cohort of HFpEF patients with detailed clinical characterization of their phenotype. 3. Set up a biobank, to analyse different biomarker profiles which will help to stratify HFpEF patients 4. Investigate if patients without HFpEF, hypertensive controls that will be included in the “HFpEF-cohort perfusion and metabolism study”( NL57468.068.16/METC162032) have different biomarker profiles compared to the HFpEF patients. 5. Isolate monocytes, neutrophils, T cells and platelets in HFpEF and hypertensive control patients included in the “HFpEF-cohort perfusion and metabolism study” (NL57468.068.16/METC162032) to understand better the pathophysiology, phenotype HFpEF patients and assess the differences with patients without HFpEF. 6. Evaluate the changes in biomarker, urine and cellular expression (monocytes, neutrophils, T cells and platelets) after one year of all HFpEF patients included in the cohort and clinically followed up in out out-patient clinic. Evaluate whether our personalized, multidisciplinary treatment strategy improves quality of life and exercise tolerability, and reduces hospitalizations 7. Increase awareness around this challenging syndrome. 8. Evaluate platelet function by analysing extracellular vesicles in blood of hypertensive control patients that in future projects will be compared to HFpEF patients.	—

Measure

Time frame

2. Set up a cohort of HFpEF patients with detailed clinical characterization of their phenotype. 3. Set up a biobank, to analyse different biomarker profiles which will help to stratify HFpEF patients 4. Investigate if patients without HFpEF, hypertensive controls that will be included in the “HFpEF-cohort perfusion and metabolism study”( NL57468.068.16/METC162032) have different biomarker profiles compared to the HFpEF patients. 5. Isolate monocytes, neutrophils, T cells and platelets in HFpEF and hypertensive control patients included in the “HFpEF-cohort perfusion and metabolism study” (NL57468.068.16/METC162032) to understand better the pathophysiology, phenotype HFpEF patients and assess the differences with patients without HFpEF. 6. Evaluate the changes in biomarker, urine and cellular expression (monocytes, neutrophils, T cells and platelets) after one year of all HFpEF patients included in the cohort and clinically followed up in out out-patient clinic. Evaluate whether our personalized, multidisciplinary treatment strategy improves quality of life and exercise tolerability, and reduces hospitalizations 7. Increase awareness around this challenging syndrome. 8. Evaluate platelet function by analysing extracellular vesicles in blood of hypertensive control patients that in future projects will be compared to HFpEF patients.

—

Contacts

Public ContactArantxa Barandiaran Aizpurua

arantxa.barandiaranaizpurua@mumc.nl

arantxa.barandiaranaizpurua@mumc.nl0640020684

Outcome results